title: Enhancing the technology of clinical trials and the trials model to evaluate newly developed, targeted antidepressants.
abstract: Concern about disappointing results from recent multi-center trials of new antidepressants prompted several ACNP workshops on "improving the technology of clinical trials." The workshops focused on technical problems, such as patient screening, reliability of clinical ratings, and the role of the placebo control. They aimed to determine how to more effectively apply the current clinical trials model for evaluating antidepressant drugs. The problems confronting the field of clinical trials, however, extend beyond technology. They also included conceptual issues concerning changes in the understanding of depressive disorders and of the multiple actions of antidepressant drugs. Such problems have been further complicated by the rapidly changing field of drug development itself, which is continually refining the targeting of new antidepressant agents. Drugs are increasingly being developed to try to change specific behavioral facets more rapidly and may be less likely, therefore, to act initially on "whole" disorders. To address such issues, a symposium was held in Rhodes in 2000 that focused on such conceptual changes with the goal of developing recommendations to revise the clinical evaluation model. Its purpose was to integrate new knowledge on depression and the mechanisms of action of antidepressant drugs toward developing more efficient methods of drug development. Since the evaluation process will eventually require changes in governmental policy, senior staff from the National Institute of Mental Health (NIMH) , Unites States and Food and Drug Administration (FDA), Unites States participated as well as members of academia, industry and clinical practice. Recommendations for altering clinical trial methodology were made in four areas: patient selection, methodology of evaluation, measuring onset of action, and FDA and NIMH perspectives on current practice. This article discusses these four areas and presents the consensus of the panel participants.
authors.affiliation: Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA. mkbsk@Worldnet.ATT.net
authors.forename: Martin M
authors.initials: MM
authors.lastname: Katz
authors.forename: Uriel M
authors.initials: UM
authors.lastname: Halbreich
authors.forename: Charles L
authors.initials: CL
authors.lastname: Bowden
authors.forename: Alan
authors.initials: A
authors.lastname: Frazer
authors.forename: Roger M
authors.initials: RM
authors.lastname: Pinder
authors.forename: A John
authors.initials: AJ
authors.lastname: Rush
authors.forename: David P
authors.initials: DP
authors.lastname: Wheatley
authors.forename: Barry D
authors.initials: BD
authors.lastname: Lebowitz
mesh_terms: D000928:Antidepressive Agents / Q000592:standards / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods / Q000592:standards*; D004341:Drug Evaluation / Q000379:methods*; D006801:Humans; D018579:Patient Selection; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000928:Antidepressive Agents